Eliem Therapeutics, Inc.
ELYM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $9,073 | $6,575 | $17,327 | $8,912 |
| G&A Expenses | $5,819 | $4,102 | $5,691 | $8,449 |
| SG&A Expenses | $5,819 | $4,102 | $5,691 | $8,449 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $51,819 |
| Operating Expenses | $14,892 | $10,677 | $23,018 | $69,180 |
| Operating Income | -$14,892 | -$10,677 | -$23,018 | -$62,570 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2,004 | $2,011 | $2,237 | $0 |
| Pre-Tax Income | -$12,888 | -$8,666 | -$20,781 | -$8,416 |
| Tax Expense | $0 | $0 | $0 | $3,008 |
| Net Income | -$12,888 | -$8,666 | -$20,781 | -$8,416 |
| % Margin | – | – | – | – |
| EPS | -0.19 | -0.13 | -0.31 | 0.47 |
| % Growth | -46.2% | 58.1% | -166% | – |
| EPS Diluted | -0.19 | -0.13 | -0.31 | 0.47 |
| Weighted Avg Shares Out | 68,003 | 67,585 | 67,462 | 67,255 |
| Weighted Avg Shares Out Dil | 68,003 | 67,585 | 67,462 | 67,255 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,037 | $2,173 | $0 | -$2,690 |
| Interest Expense | $0 | $0 | $0 | -$1,148 |
| Depreciation & Amortization | $29 | $0 | $0 | -$6,060 |
| EBITDA | -$12,859 | -$10,677 | -$23,018 | -$10,911 |
| % Margin | – | – | – | – |